Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily oral deucrictibant prophylaxis in acquired C1 inhibitor deficiency
2022-003168-25Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of deucrictibant in acquired C1 esterase inhibitor deficiency (AAE), sponsored by Amsterdam University Medical Center. Primary endpoint: Normalized number of investigator-confirmed angioedema attacks. Started Feb 2023; status: completed.
02
Drugs
deucrictibant
03
Conditions
acquired C1 esterase inhibitor deficiency (AAE)
Beyond the preview
Go deeper on 2022-003168-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003168-25.